OnKure Therapeutics, Inc. (OKUR)

OnKure Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	7.96	29.88	11.54
Cash & Short-Term Investments	7.96	29.88	11.54
Cash Growth	-31.05%	158.82%	-
Prepaid Expenses	4	3.89	2.08
Total Current Assets	11.96	33.77	13.62
Property, Plant & Equipment	1.49	1.91	2.05
Other Long-Term Assets	0.06	0.06	0.33
Total Assets	13.51	35.73	16
Accounts Payable	8.19	3.42	2.52
Accrued Expenses	3.92	3.66	2.87
Current Portion of Leases	0.22	0.21	0.15
Total Current Liabilities	18.43	7.29	5.54
Long-Term Leases	0.3	0.47	0.49
Total Liabilities	18.73	7.75	6.03
Common Stock	0	0	0
Additional Paid-In Capital	2.23	0.21	2.66
Retained Earnings	-137.28	-102.05	-57.07
Total Common Equity	-135.05	-101.84	-54.42
Shareholders' Equity	-5.23	27.98	9.97
Total Liabilities & Equity	13.51	35.73	16
Total Debt	6.51	0.67	0.64
Net Cash (Debt)	1.45	29.2	10.91
Net Cash Growth	-86.68%	167.76%	-
Net Cash Per Share	0.11	2.42	-
Filing Date Shares Outstanding	13.4	13.34	-
Total Common Shares Outstanding	13.4	13.34	-
Working Capital	-6.48	26.48	8.08
Book Value Per Share	-10.08	-7.63	-
Tangible Book Value	-135.05	-101.84	-54.42
Tangible Book Value Per Share	-10.08	-7.63	-
Machinery	1.04	1.01	0.85
Leasehold Improvements	1.09	1.09	1

Source: S&P Capital IQ. Standard template. Financial Sources.